Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer

Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer

Although the recently approved prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) [177Lu]Lu-PSMA-617 has improved outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), not all patients respond optimally to this treatment; even measuring respons...

Full description

Saved in:

Bibliographic Details
Main Authors:	Himisha Beltran, Jeremie Calais, Louise Emmett, Phillip H. Kuo, Christopher J. Logothetis
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Oncology
Subjects:	metastatic castration-resistant prostate cancer prostate-specific membrane antigen radioligand therapy [177Lu]Lu-PSMA-617 biomarkers
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1583168/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials
by: Alexander Konopnicki, et al.
Published: (2024-12-01)

LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES
by: K. Kairemo, et al.
Published: (2018-03-01)

Efficacy of <sup>177</sup>Lu-PSMA-617 Therapy in mCRPC Patients with Liver Metastases: Insights into Survival Outcomes and Predictors of Response
by: Ebuzer Kalender, et al.
Published: (2025-02-01)

USE OF <sup>177</sup>Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER
by: A. A. Medvedeva, et al.
Published: (2021-06-01)

Improvement of End-of-Synthesis Radiochemical Purity of <sup>177</sup>Lu-DOTA-PSMA-Ligands with Alternative Synthesis Approaches: Conversion Upswing and Side-Products Minimization
by: Anton Larenkov, et al.
Published: (2024-11-01)

Comparison of tumour segmentation methods for dosimetry in [177Lu]Lu-PSMA I&T treated patients with metastatic castration resistant prostate cancer
by: Peter Frøhlich Staanum, et al.
Published: (2025-07-01)

Stability in the production and transport of 177Lu labelled PSMA
by: Cristian Antonio Wieczorek Villas Boas, et al.
Published: (2021-03-01)

Theranostic Potential of the iPSMA-Bombesin Radioligand in Patients with Metastatic Prostate Cancer: A Pilot Study
by: Sofía González-Rueda, et al.
Published: (2024-10-01)

Actinium-225-PSMA-617 treatment in a patient with advanced prostate cancer causes secondary myelofibrosis: a case report and literature review
by: Ziye Wang, et al.
Published: (2025-07-01)

Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial
by: Aaron R. Hansen, et al.
Published: (2025-01-01)

A proof-of-concept study of personalized dosimetry for targeted radioligand therapy using pre-treatment diagnostic dynamic PET/CT and Monte Carlo simulation
by: Thanh Tai Duong, et al.
Published: (2025-08-01)

<sup>225</sup>Aс-PSMA-617 therapy in metastatic castration-resistant prostate cancer
by: T. Yu. Kochetova, et al.
Published: (2025-01-01)

Personalized three-dimensional dose calculation method based on multi-modal images in dosimetry assessment of prostate cancer with skull metastasis: a Monte Carlo simulation study
by: Feng Tian, et al.
Published: (2025-07-01)

The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study
by: Atefeh Zamanian, et al.
Published: (2025-07-01)

Study of predictive factors for response to 177LU-PSMA in patients with metastatic castration-resistant prostate cancer
by: Hugo Peslier, et al.
Published: (2025-03-01)

Investigating the significance of SPECT/CT-SUV for monitoring 177Lu-PSMA-targeted radionuclide therapy: a systematic review
by: Tahani O. Alkahtani
Published: (2025-01-01)

Analysis of innovative clinical developments in the field of therapy for metastatic prostate cancer: bright results of the ASCO Congress-2022
by: D. A. Andreev, et al.
Published: (2022-06-01)

Predictive factors for persistent thrombocytopenia after peptide receptor radioligand therapy in enteropancreatic neuroendocrine tumors
by: Romain Ferrara, et al.
Published: (2025-05-01)

177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
by: Majid Assadi, et al.
Published: (2019-10-01)

Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia
by: Moritz B. Bastian, et al.
Published: (2025-07-01)

Hematological toxicity of [225Ac]Ac-PSMA-617 and [177Lu]Lu-PSMA-617 in RM1-PGLS syngeneic mouse model
by: Meryl Maria Vilangattil, et al.
Published: (2025-03-01)

On the feasibility of producing Lu-177 in the IEA-R1 reactor via the direct route
by: Guilherme Soares Zahn, et al.
Published: (2021-04-01)

Metastasis directed radiotherapy versus standard of care for PSMA-PET diagnosed oligometastatic/oligoprogressive castration resistant prostate cancer
by: Laura Bauersachs, et al.
Published: (2025-07-01)

Physician and Patient Preferences for the Treatment of Metastatic Castration-Sensitive and Castration-Resistant Prostate Cancer: A Best-Worst Scaling Study in Japan
by: Takahiro Kimura, et al.
Published: (2025-02-01)

[225Ac]Ac-PSMA-617 production method: development of an efficient and reproducible radiolabelling process for establish a clinical routine production
by: Michela Aurilio, et al.
Published: (2025-05-01)

Comparative Study of P507-impregnated Polystyrene and Polyacrylate Resins for Separation of Yb/Lu
by: FAN Xisheng, MA Guoquan, PENG Haiyue, GAO Jing, LI Feize, LAN Tu, LIAO Jiali, YANG Yuanyou, LIU Ning
Published: (2025-01-01)

Combined treatment with anti-PSMA antibody and human peripheral blood-derived NK cells for castration-resistant prostate cancer
by: Fangming Wang, et al.
Published: (2025-05-01)

Experience with using fosfestrol for treating metastatic castrate-resistant prostate cancer in resource-limited setting
by: Jayachandran Perumal Kalaiyarasi, et al.
Published: (2019-01-01)

Blood-based transcriptomic biomarkers for response to [177Lu]Lu-DOTA-TATE therapy in neuroendocrine tumors
by: Hyunpil Sung, et al.
Published: (2025-08-01)

Synthesis of DOTA-Based <sup>43</sup>Sc Radiopharmaceuticals Using Cyclotron-Produced <sup>43</sup>Sc as Exemplified by [<sup>43</sup>Sc]Sc-PSMA-617 for PSMA PET Imaging
by: Jason P. Meier, et al.
Published: (2025-06-01)

Clinical observations of patients with metastatic castration-resistant prostate cancer living in the Tambov region
by: P. G. Berezin, et al.
Published: (2023-09-01)

Which PSMA PET/CT interpretation criteria most effectively diagnose prostate cancer? a retrospective cohort study
by: Le Ma, et al.
Published: (2025-01-01)

The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Metastatic Castrate-Sensitive Prostate Cancer Patients Treated with Abiraterone Acetate
by: Caio Vinícius Suartz, et al.
Published: (2024-08-01)

The South Australian 177Lu-DOTATATE peptide receptor radionuclide therapy service: an 11-year review of toxicity, health-related quality of life, and survival
by: L.M. Altus, et al.
Published: (2025-06-01)

Utility of pembrolizumab for metastatic castrate resistant prostate cancer with MMR deficiency
by: Brian F. Dinerman, et al.
Published: (2024-11-01)

Therapeutic outcomes of enzalutamide-docetaxel combination versus docetaxel monotherapy in post-sequential androgen receptor axis-targeted therapy failure metastatic castration-resistant prostate cancer
by: Zhiyu Zhang, et al.
Published: (2025-08-01)

Predictors of renal function decline in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy
by: Felix L. Herr, et al.
Published: (2025-08-01)

Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study
by: Rachele Danieli, et al.
Published: (2024-11-01)

Radiation exposure and protection advice after [177Lu]Lu-DOTA-TATE therapy in China
by: Fei Liu, et al.
Published: (2024-11-01)

Adverse prognosis gene expression patterns in metastatic castration‐resistant prostate cancer
by: Marina N. Sharifi, et al.
Published: (2025-08-01)